Ceruloplasmin immunoreactivity in neurodegenerative disorders

References

• Gutteridge J.M.C., Stocks J. Caeruloplasmin: physiological and pathological perspectives. CRC Critical Reviews in Clinical Laboratory Science 1981; 14: 257–329
   PubMed Web of Science ®Google Scholar
• Stocks J., Gutteridge J.M.C., Sharp R.J., Dormandy T.L. The inhibition of lipid autoxidation by human serum and its relation to serum proteins and α-tocopherol. Clinical Science and Molecular Medicine 1974; 47: 223–233
   PubMedGoogle Scholar
• Osaki S., Johnson D.A., Frieden E. The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. Journal of Biological Chemistry 1966; 241: 2746–2751
   PubMed Web of Science ®Google Scholar
• Goldstein I.M., Charo I.F. Ceruloplasmin: an acute phase reactant and anti-oxidant. Lymphokines 1982; 8: 373–411
   Google Scholar
• Swain J.A., Darley-Usmar V., Gutteridge J.M.C. Peroxynitrite releases copper from caeruloplasmin: implications for atherosclerosis. FEBS Letters 1994; 342: 49–52
   PubMed Web of Science ®Google Scholar
• Kim R.H., Park J.E., Park J.-W. Ceruloplasmin enhances DNA damage induced by hydrogen peroxide in vitro. Free Radical Research 2000; 33: 81–89
   PubMed Web of Science ®Google Scholar
• Cohen G. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Annals of the New York Academy of Sciences 2000; 899: 112–120
   PubMedGoogle Scholar
• Markesbery W.R., Carney J.M. Oxidative alterations in Alzheimer's disease. Brain Pathology 1999; 9: 133–146
   PubMed Web of Science ®Google Scholar
• Polidori M.C., Mecocci P., Browne S.E., Senin U., Beal M.F. Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neuroscience Letters 1999; 272: 53–56
   PubMed Web of Science ®Google Scholar
• Albers D.S., Augood S.J., Marind D.M., Standaert D.G., Vonsattel J.P., Beal M.F. Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy. Journal of Neurochemistry 1999; 73: 881–884
   PubMed Web of Science ®Google Scholar
• Gutteridge J.M.C. Hydroxyl radicals, iron, oxidative stress, and neurodegeneration. Annals of New York Academy of Sciences 1994; 738: 201–213
   PubMed Web of Science ®Google Scholar
• Evans P.H. Free radicals in brain metabolism and pathology. British Medical Bulletin 1993; 49: 577–587
   PubMed Web of Science ®Google Scholar
• Loeffler D.A., LeWitt P.A., Juneau P.L., Sima A.A.F., Nguyen H.-U., DeMaggio A.J., Brickman C.M., Brewer G.J., Dick R.D., Troyer M.D., Kanaley L. Increased ceruloplasmin concentrations in Alzheimer's and Parkinson's disease brain regions. Brain Research 1996; 738: 265–274
   PubMed Web of Science ®Google Scholar
• Castellani R.J., Smith M.A., Nunomura A., Harris P.L.R., Perry G. Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin?. Free Radical Biology and Medicine 1999; 26: 1508–1512
   Google Scholar
• Harris Z.L., Takahashi Y., Miyajima H., Serizawa M., MacGillvray R.T.A., Gitlin J.D. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proceedings of the National Academy of Sciences USA 1995; 92: 2539–2543
   PubMed Web of Science ®Google Scholar
• Yoshida K., Kaneko K., Miyajima H., Tokuda T., Nakamura A., Kato M., Ikeda S. Increased lipid peroxidation in the brains of aceruloplasminemia patients. Journal of Neurological Sciences 2000; 175: 91–95
   PubMed Web of Science ®Google Scholar
• Connor J.R., Tucker P., Johnson M., Snyder B. Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer's disease. Neuroscience Letters 1993; 159: 88–90
   PubMed Web of Science ®Google Scholar
• Loeffler D.A., Linder M.C., Zamany M., Harel E., Paul M.A., Baumann H., LeWitt P.A. Measurement of acute phase proteins in the rat brain: contribution of vascular contents. Neurochemical Research 1999; 24: 1313–1317
   Google Scholar
• Khachaturian Z.S. Diagnosis of Alzheimer's disease. Archives of Neurology 1985; 42: 1097–1105
   PubMed Web of Science ®Google Scholar
• Vonsattel J.-P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P., Jr. Neuropathological classification of Huntington's disease. Journal of Neuropathology and Experimental Neurology 1985; 44: 559–577
   PubMed Web of Science ®Google Scholar
• Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II, Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479–486
   PubMed Web of Science ®Google Scholar
• Hauw J.-J., Daniel S.E., Dickson D., Haroupian D.S., Jellinger K., Lantos P.L., McKee A., Tabaton M., Litvan I. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994; 44: 2015–2019
   PubMed Web of Science ®Google Scholar
• Forno L.S. Neuropathology of Parkinson's disease. Journal of Neuropathology and Experimental Neurology 1996; 55: 259–272
   PubMed Web of Science ®Google Scholar
• Hancock M.B. Visualization of peptide-immuno-reactive processes of serotonin-immunoreactive cells using two color immunoperoxidase staining. Journal of Histochemistry and Cytochemistry 1984; 32: 311–314
   PubMed Web of Science ®Google Scholar
• Patel B.N., David S. A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes. Journal of Biological Chemistry 1997; 272: 20185–20190
   PubMed Web of Science ®Google Scholar
• Salzer J.L., Lovejoy L., Linder M.C., Rosen C. Ran-2, a glial lineage marker, is a GPI-anchored form of ceruloplasmin. Journal of Neuroscience Research 1998; 54: 147–157
   Google Scholar
• Klomp L.W.J., Gitlin J.D. Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Human Molecular Genetics 1996; 5: 1989–1996
   PubMed Web of Science ®Google Scholar
• Griffin W.S.T., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L., III, Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proceedings of the National Academy of Sciences USA 1989; 86: 7611–7615
   PubMed Web of Science ®Google Scholar
• Subbarao K.V., Richardson J.S., Ang L.C. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. Journal of Neurochemistry 1990; 55: 342–345
   PubMed Web of Science ®Google Scholar
• Lovell M.A., Ehmann W.D., Butler S.M., Markesbery W.R. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995; 45: 1594–1601
   PubMed Web of Science ®Google Scholar
• Klomp L.W.J., Farhangrazi Z.S., Dugan L.L., Gitlin J.D. Ceruloplasmin gene expression in the murine central nervous system. Journal of Clinical Investigation 1996; 98: 207–215
   PubMed Web of Science ®Google Scholar
• Orena S.J., Goode C.A., Linder M.C. Binding and uptake of copper from ceruloplasmin. Biochemical and Biophysical Research Communications 1986; 139: 822–829
   PubMedGoogle Scholar
• Linder M.C., Moore J.R. Plasma ceruloplasmin: evidence for its presence in and uptake by heart and other organs of the rat. Biochimica Biophysica Acta 1977; 499: 329–336
   PubMed Web of Science ®Google Scholar